+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Xerostomia - Pipeline Insight, 2020

  • PDF Icon

    Clinical Trials

  • 60 Pages
  • December 2020
  • Region: Global
  • DelveInsight
  • ID: 4989310
This “Xerostomia - Pipeline Insight, 2020,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Xerostomia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage

Xerostomia Understanding

Xerostomia: Overview

Xerostomia is defined as dry mouth resulting from reduced salivary flow. Xerostomia is not a disease, but is a condition of various medical conditions like systemic lupus erythematosus, scleroderma, sarcoidosis, amyloidosis, Sjögren's syndrome etc. It can also be due to the side effect of drugs like antihistamines, antidepressants, anticholinergics, anorexiants, and antihypertensives among others. It may or may not be associated with decreased salivary gland function. Xerostomia is often a contributing factor for both minor and serious health problems. Long-standing xerostomia can result in severe tooth decay and oral candidiasis. It is a commonly observed condition among older adults, affecting about 20%, but the disease is not related with age, it may be due to medication.


The symptoms of Xerostomia include:
  • Taste disorders (dysgeusia),
  • A painful tongue (glossodynia) and
  • An increased need to drink water, especially at night.
  • Bad breath
  • Cheilitis, or inflammation and fissuring (splitting or cracking) of the lips
  • Dryness in the mouth
  • Fungal infections in the mouth, such as thrush
  • Inflammation of the tongue, tongue ulcers
  • More tooth decay and plaque


A diagnosis of Xerostomia is based on evidence obtained from the patient's history, an examination of the oral cavity and/or sialometry. Blood test and Imaging test may also be done. Sialography is an imaging technique that may be useful in identifying salivary gland stones and masses. Salivary scintigraphy can be useful in assessing salivary gland function. Biopsy can be suggested, if malignancy (cancer) is suspected.


Treatment for Xerostomia depends on various factors such as whether the patient has an underlying condition or disease, or is taking certain medications that may be causing dry mouth. In case, the condition is because of medication, the doctor will either change the dosage or prescribe another drug. Symptomatic treatment for the condition typically includes: increasing the flow of saliva, replacing lost secretions, controlling dental caries, and specific measures, such as treating infections. Drugs like pilocarpine (Salagen) or cevimeline (Evoxac) are prescribed to stimulate saliva production.

Xerostomia Emerging Drugs Chapters

This segment of the Xerostomia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Xerostomia Emerging Drugs

LBS-020: Lubris Biopharma

LBS-020 is a recombinant lubricin and a glycoprotein stimulant. It is currently under Phase II development for the treatment of Xerostomia. Recombinant lubricin. Lubricin is a large endogenous complex glycoprotein that binds to, and protects tissue surfaces from friction.

AAV-AQP1: Kadmon Gene Therapy

AAV-AQP1 is an Adeno-associated virus vector containing gene therapy that contains the human aquaporin-1 gene (AAV2hAQP1) for the treatment of Xerostomia. It works on Aquaporin 1 replacement mechanism. It is currently under Phase I/II stage of development.

Xerostomia: Therapeutic Assessment

This segment of the report provides insights about the different Xerostomia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Xerostomia

There are approx. 4+ key companies which are developing the therapies for Xerostomia. The companies which have their Xerostomia drug candidates in the most advanced stage, i.e. phase II include, Lubris Biopharma.


This report covers around 4+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Xerostomia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Xerostomia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Xerostomia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Xerostomia drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Xerostomia R&D. The therapies under development are focused on novel approaches to treat/improve Xerostomia.

Xerostomia Report Insights
  • Xerostomia Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Xerostomia Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Xerostomia drugs?
  • How many Xerostomia drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Xerostomia?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Xerostomia therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Xerostomia and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players
  • Lubris Biopharma
  • Kadmon Gene Therapy Holdings

Key Products

LBS-020: Lubris Biopharma
  • AAV-AQP1

This product will be delivered within 1-3 business days.

Table of Contents


Executive Summary

Xerostomia: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Xerostomia- Analytical Perspective

In-depth Commercial Assessment
  • Xerostomia companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Xerostomia Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase II)
  • Comparative Analysis

LBS-020: Lubris Biopharma
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)
  • Comparative Analysis

AAV-AQP1: Kadmon Gene Therapy
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Xerostomia Key Companies

Xerostomia Key Products

Xerostomia- Unmet Needs

Xerostomia- Market Drivers and Barriers

Xerostomia- Future Perspectives and Conclusion

Xerostomia Analyst Views

Xerostomia Key Companies

AppendixList of Tables
Table 1 Total Products for Xerostomia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Xerostomia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Lubris Biopharma
  • Kadmon Gene Therapy Holdings